Genes Dev 14:2501–2514CrossRefPubMed 44. Murtagh J, Lu H, Schwartz EL (2006) Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. Cancer Res 66:8192–8199CrossRefPubMed 45. Sato S, Fujita N, Tsuruo T (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97:10832–10837CrossRefPubMed 46. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175–1183CrossRefPubMed
47. Hagemann T, Lawrence T, McNeish I et VX-689 chemical structure al (2008) “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205:1261–1268CrossRefPubMed 48. Cahill CM, Rogers JT (2008) Interleukin (IL) 1beta induction of Angiogenesis inhibitor IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha AZD1152 datasheet pathway targeting activator protein-1. J Biol Chem 283:25900–25912CrossRefPubMed 49. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501CrossRefPubMed 50. Oda K, Okada J, Timmerman L et al (2008) PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations
to effect oncogenic transformation. Cancer Res 68:8127–8136CrossRefPubMed 51. Parsons DW, Wang TL, Samuels Y et al (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436:792CrossRefPubMed 52. Jhawer M, Goel S, Wilson AJ et al (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68:1953–1961CrossRefPubMed 53. Maeda S, Hsu LC, Liu H et al (2005) Nod2 mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta processing. Science 307:734–738CrossRefPubMed 54. Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment
by inhibition of cyclooxygenase-2. Nat Rev Cancer 1:11–21CrossRefPubMed 55. He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta Farnesyltransferase is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335–345CrossRefPubMed 56. O’Neill EA (1998) A new target for aspirin. Nature 396:15 17CrossRefPubMed 57. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77–80CrossRefPubMed”
“Introduction Prostate cancer is the most diagnosed cancer and the second leading cause of mortality from cancer among American men [1]. Surgery, hormone therapy and radiation therapy remain the treatments of choice for the early (localized) stages of prostate cancer. Despite these treatments a significant population of men have recurrent disease suggesting the presence of occult tumors in this patient group. There is currently no effective treatment for these patients with recurrent metastatic disease.